Solid Tumors Challenges and New Insights of CAR T Cell Engineering
- PMID: 31161552
- DOI: 10.1007/s12015-019-09901-7
Solid Tumors Challenges and New Insights of CAR T Cell Engineering
Abstract
Adoptive cell therapy using CAR T cells has emerged as a novel treatment strategy with promising results against B cell malignancies; however, CAR T cells have not shown much success against solid malignancies. There are several obstacles which diminish the efficacy of CAR T cells, but the immunosuppressive tumor microenvironment (TME) of the tumor stands out as the most important factor. TME includes Tumor-Associated Stroma, Immunosuppressive cells and cytokines, tumor hypoxia and metabolism, and Immune Inhibitory Checkpoints which affect the CAR T cell efficacy and activity in solid tumors. A precise understanding of the TME could pave the way to engineer novel modifications of CAR T cells which can overcome the immunosuppressive TME. In this review, we will describe different sections of the TME and introduce novel approaches to improve the CAR T cells potential against solid tumors based on recent clinical and preclinical data. Also, we will provide new suggestions on how to modify CARs to augment of CAR T cells efficacy. Since there are also some challenges beyond the TME that are important for CAR function, we will also discuss and provide data about the improvement of CAR T cells trafficking and delivery to the tumor site and how to solve the problem of tumor antigen heterogeneity.
Keywords: Adoptive cell therapy; CAR T cell; Challenges; Chimeric antigen receptor; Immunotherapy; Solid tumor.
Similar articles
-
Advances in CAR-T Cell Genetic Engineering Strategies to Overcome Hurdles in Solid Tumors Treatment.Front Immunol. 2022 Feb 8;13:830292. doi: 10.3389/fimmu.2022.830292. eCollection 2022. Front Immunol. 2022. PMID: 35211124 Free PMC article. Review.
-
Manipulating the tumor microenvironment by adoptive cell transfer of CAR T-cells.Mamm Genome. 2018 Dec;29(11-12):739-756. doi: 10.1007/s00335-018-9756-5. Epub 2018 Jul 9. Mamm Genome. 2018. PMID: 29987406 Review.
-
Engineering CAR-T Cells for Next-Generation Cancer Therapy.Cancer Cell. 2020 Oct 12;38(4):473-488. doi: 10.1016/j.ccell.2020.07.005. Epub 2020 Jul 30. Cancer Cell. 2020. PMID: 32735779 Review.
-
Engineered Cytokine Signaling to Improve CAR T Cell Effector Function.Front Immunol. 2021 Jun 4;12:684642. doi: 10.3389/fimmu.2021.684642. eCollection 2021. Front Immunol. 2021. PMID: 34177932 Free PMC article. Review.
-
Advances in CAR T cell therapy: antigen selection, modifications, and current trials for solid tumors.Front Immunol. 2025 Jan 6;15:1489827. doi: 10.3389/fimmu.2024.1489827. eCollection 2024. Front Immunol. 2025. PMID: 39835140 Free PMC article. Review.
Cited by
-
Commentary: Long-term in vivo microscopy of CAR T cell dynamics during eradication of CNS lymphoma in mice.Front Immunol. 2020 Jul 21;11:1503. doi: 10.3389/fimmu.2020.01503. eCollection 2020. Front Immunol. 2020. PMID: 32793205 Free PMC article. No abstract available.
-
Harnessing 3D in vitro systems to model immune responses to solid tumours: a step towards improving and creating personalized immunotherapies.Nat Rev Immunol. 2024 Jan;24(1):18-32. doi: 10.1038/s41577-023-00896-4. Epub 2023 Jul 4. Nat Rev Immunol. 2024. PMID: 37402992 Review.
-
Significant Advancements and Evolutions in Chimeric Antigen Receptor Design.Int J Mol Sci. 2024 Nov 13;25(22):12201. doi: 10.3390/ijms252212201. Int J Mol Sci. 2024. PMID: 39596267 Free PMC article. Review.
-
Any closer to successful therapy of multiple myeloma? CAR-T cell is a good reason for optimism.Stem Cell Res Ther. 2021 Mar 29;12(1):217. doi: 10.1186/s13287-021-02283-z. Stem Cell Res Ther. 2021. PMID: 33781320 Free PMC article. Review.
-
CAR-T Cells in Acute Myeloid Leukemia: Where Do We Stand?Biomedicines. 2024 May 28;12(6):1194. doi: 10.3390/biomedicines12061194. Biomedicines. 2024. PMID: 38927401 Free PMC article. Review.
References
-
- Elahi, R., Khosh, E., Tahmasebi, S., & Esmaeilzadeh, A. (2018). Immune cell hacking: Challenges and clinical approaches to create smarter generations of chimeric antigen receptor T cells. Frontiers in Immunology, 9. https://doi.org/10.3389/fimmu.2018.01717 .
-
- Junghans, R. P., Ma, Q., Rathore, R., Gomes, E. M., Bais, A. J., Lo, A. S., et al. (2016). Phase I trial of anti-PSMA designer CAR-T cells in prostate Cancer: Possible role for interacting interleukin 2-T cell pharmacodynamics as a determinant of clinical response. The Prostate., 76(14), 1257–1270. - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources